Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 in Combination With Chemotherapy for NSCLC
NCT04736823Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2021
- Primary completion
- Jul 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started Feb 2021; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04736823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736823.